Undetected SARS-CoV-2 transmission in a Malawian pregnancy cohort: A longitudinal serological surveillance study

Publication date: Jun 22, 2025

Background: Despite COVID-19’s global impact, surveillance remains challenging in resource-limited settings. This study investigated IgG to SARS-CoV-2 antigens in Malawian pregnant women participating in the REVAMP trial, where no COVID-19 clinical cases or positive SARS-CoV-2 tests were reported during the pandemic (April 2020 to September 2021). Methods: We analysed serum samples collected from November 2018 to September 2021 from 852 pregnant women at enrolment (second trimester) and delivery, measuring IgG against five SARS-CoV-2 antigens using a multiplex bead assay. IgG to Tetanus toxoid served as a positive control, and IgG to four seasonal coronavirus antigens and Influenza A were used for context. Findings: Women recruited after the start of the pandemic were younger than those recruited before the emergence of COVID-19 (median age 19 vs 21 years) and more likely primigravid (60.1% vs 51.1%). IgG levels to SARS-CoV-2 antigens showed sharp increases of 18.5% – 29.7% every 30 days during COVID waves 2 and 3. Overall seropositivity to SARS-CoV-2 antigens reached 39.3% during the pandemic; however, the 14.7% seropositivity detected pre-pandemic demonstrates the presence of cross-reactive antibody responses against other antigens in Malawi. Surprisingly, pregnancies within the pandemic showed improved outcomes, with longer gestations (mean difference: 0.6 weeks [95% CI: 0.2 – 0.9]) and higher birth weights (mean difference: 169.3g, [65.9 – 272.6]) when compared to pregnancies occurring pre-pandemic. We found no evidence that SARS-CoV-2 IgG levels were associated with pregnancy outcomes. Interpretations: This study demonstrates that serological surveillance reveals undetected SARS-CoV-2 exposure where traditional testing was limited. The improvement in pregnancy outcomes during the pandemic suggests community-level exposure did not offset the social impacts of the pandemic in this population. These findings highlight pregnancy cohorts as valuable sentinel populations for infectious disease surveillance, emphasising the importance of serosurveillance in resource-limited settings.

PDF

Concepts Keywords
Malaria Antigens
Malawian Cov
Phd14 Covid
Pregnancy Igg
Limited
Malawi
Medrxiv
Pandemic
Pregnancy
Preprint
Sars
Serological
Surveillance
Trial
Women

Semantics

Type Source Name
disease MESH COVID-19
disease IDO assay
drug DRUGBANK Clostridium tetani toxoid antigen (formaldehyde inactivated)
pathway KEGG Influenza A
disease MESH pregnancy outcomes
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH Infection
drug DRUGBANK Huperzine B
disease MESH Influenza
drug DRUGBANK Iron
disease IDO blood
disease MESH malaria
pathway KEGG Malaria
disease MESH tetanus
drug DRUGBANK Ferric Carboxymaltose
drug DRUGBANK Methionine

Download Document

(Visited 5 times, 1 visits today)